

## FINAL PROGRAMME

### Friday, 12<sup>th</sup> March

|             |  |
|-------------|--|
| 14.00-14.30 | Registration   |
| 15.00-15.30 | <b>Prof. D. Raptopoulos</b><br><b>Prof. Ch. Papakonstantinou</b>   |
| 15.30-16.00 | <b>Anaesthesia in Pigs – Dr. I. Savas</b><br><b>Surgery in Pigs; what's common in humans – Dr. L. Papazoglou</b>   |
| 16.00-17.30 | <b>PRINCIPLES OF THORACOSCOPY</b><br>Chairmen: Prof. D. Raptopoulos, Prof. Ch. Papakonstantinou<br><b>ANAESTHESIA FOR THORACOSCOPY:</b> Dr. E. Chrona<br><b>VATS: HISTORY &amp; PRINCIPLES:</b> Dr. K. Athanassiadi<br><b>MEDICAL THORACOSCOPY:</b> Dr. E. Balis<br><b>SURGICAL THORACOSCOPY:</b> Dr. K. Iliadis |
| 17.30-18.00 | Coffee break   |
| 18.00-19.30 | <b>PLEURAL DISEASES</b><br>Chairmen: Dr. Iliadis, Dr. G. Marulli<br><b>PNEUMOTHORAX:</b> Dr. I. Papachristos<br><b>MESOTHELIOMA :</b> Dr. I. Papachristos<br><b>EMPHYEMA:</b> Dr. N. Anastasiou<br><b>LUNG VOLUME REDUCTION SURGERY:</b> Dr. N. Anastasiou   |

### Saturday, 13<sup>th</sup> March

|               |  |
|---------------|--|
| 09.00 - 13.00 | <b>Hands-on Workshop</b>   |
| 13.00-14.00   | Light lunch with tutors  |
| 14.00 - 16.00 | <b>MEDIASTINUM &amp; INFECTIONS</b><br>Chairmen: Dr. N. Anastasiou, Dr. K. Anastasiadis<br><b>MEDIASTINAL LESIONS:</b> Dr. K. Iliadis<br><b>PULMONARY HYDATIDOSIS:</b> Dr. K. Athanassiadi<br><br><b>BRONCHOSCOPY</b><br><b>FLEXIBLE &amp; RIGID BRONCHOSCOPY; FILMS:</b> Dr. E. Balis & Dr. K. Athanassiadi<br><b>EBUS:</b> Dr. K. Kotsifas |
| 16.00-16.30   | Coffee break   |
| 16.30-19.00   | <b>HOW TO DO IT! –TIPPS</b><br>Chairmen: Dr. K. Athanassiadi, Dr. K. Iliadis<br><b>CHEST WALL – NUSS PROCEDURE:</b> Prof. M. Yukzel<br><b>Thymectomy : VATS – ROBOTICS:</b> Dr. G. MARULLI<br><b>ROBOTICS –VATS LOBECTOMY:</b> Dr. F. Melfi<br><b>META-ANALYSIS OF VATS LOBECTOMY:</b> Prof. R. Schmid                                       |
| 21.00         | Dinner (tutors & students)   |

### Sunday, 14<sup>th</sup> March

|               |                          |
|---------------|--------------------------|
| 09.00 - 12.00 | <b>Hands-on Workshop</b> |
| 12.30-13.00   | <b>Conclusions</b>       |

## Hands-on Thoracoscopic Workshop


**March 12-14, 2010**  
**Thessaloniki, Greece**

*Under the Auspices of:*  
*European Association of Cardiothoracic Surgery*  
*Hellenic Society of Cardiothoracic & Vascular Surgery*

Secretariat: E-mail: [agronca@otenet.gr](mailto:agronca@otenet.gr)

# Mesothelioma

Lt. Col. Ioannis Ch. PAPACHRISTOS



Consultant Thoracic Surgeon  
The "424" Military General Hospital, Thessaloniki, Greece  
**ESTS** Regent for Greece

12.3.2010

## Overview - 1

- **Rare** malignant neoplasm
- $\approx$  2,500 people in the US every year
- It can affect the **pleurae** (both parietal & visceral), the **pericardium** and the **peritoneum**
- Deadly disease
- Extremely difficult to treat & to achieve reasonably optimistic end-results
- Median Overall survival **1 yr**
- Usually older men, aged 72-yr





## Overview - 2

- Previous exposure to **asbestos**
  - latency period: 20-40 yrs
  - Shipyards, vehicles' brakes, fire-resistant materials for roofs, tiles, fireplaces etc
- Radiotherapy and viruses (SV-40 etc) may also be associated with mesothelioma
- Histology subtypes:
  - Epithelioid (common)
  - Sarcomatoid
  - Biphasic or mixed



## Asbestos:


|           |            |
|-----------|------------|
| Muscovite | Chrysotile |
|-----------|------------|




## Forms of Asbestos



## Asbestos Fibres



Anthophyllite



## Controversies


- Once therapeutic Nihilism was usually the case amongst physicians because of MPM's poorest prognosis despite radical attempts to Rx
- Extremely aggressive & radical Ops alone did not offer chances for cure:
  - Pleuropneumonectomy or Extrapleural pneumonectomy
- Multimodality Rx achieved some relatively better results occasionally
- Lesser surgical Ops nowadays carried out

## Diagnosis

- Dyspnoea
- Chest pain
- Pleural effusion
- Cough
- Chest wall/pleural Mass(es)
- CT scanning
- Thoracentesis for Cytology
- **VATS** – Bx (preferred) or CT-guided needle Bx of pleura







## Stage: $T_x$ , $T_0$ , $T_1$ , $T_2$

### IMIG Staging System for Diffuse Malignant Pleural Mesothelioma\*

#### T Primary Tumor

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- T1 Tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement
- T1a No involvement of the visceral pleura
- T1b Tumor also involving the visceral pleura
- T2 Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with a least one of the following:
- Involvement of the diaphragmatic muscle
  - Extension of tumor from visceral pleura into the underlying pulmonary parenchyma

## Stage: T<sub>3</sub>, T<sub>4</sub>

|    |   |
|----|---|
| T3 | Locally advanced but potentially resectable tumor<br>Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura), with at least one of the following:<br>-Involvement of the endothoracic fascia<br>-Extension into the mediastinal fat<br>-Solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall<br>-Nontransmural involvement of the pericardium   |
| T4 | Locally advanced technically unresectable tumor<br>Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:<br>-Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction<br>-Direct transdiaphragmatic extension of the tumor to the<br>-Direct extension of tumor to the contralateral pleura<br>-Direct extension of the tumor to mediastinal organs<br>-Direct extension of tumor into the spine<br>-Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion or tumor involving the myocardium |

## Stage: N, M

|          |   |
|----------|---|
| <b>N</b> | <b>Regional Lymph Nodes</b>   |
| NX       | Regional lymph nodes cannot be assessed   |
| N0       | No regional lymph node metastasis   |
| N1       | Metastasis to the ipsilateral bronchopulmonary or hilar lymph nodes   |
| N2       | Metastases in the subcarinal lymph node or the ipsilateral mediastinal lymph nodes including the ipsilateral internal mammary and peridiaphragmatic nodes |
| N3       | Metastasis in contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular lymph nodes                         |
| <b>M</b> | <b>Distant Metastasis</b>   |
| M0       | No distant metastasis   |
| M1       | Distant metastasis  |


## Stage

| Stage | T      | N          | M  |
|-------|--------|------------|----|
| I     | T1     | N0         | M0 |
| IA    | T1a    | N0         | M0 |
| IB    | T1b    | N0         | M0 |
| II    | T2     | N0         | M0 |
| III   | T1, T2 | N1         | M0 |
|       | T1, T2 | N2         | M0 |
|       | T3     | N0, N1, N2 | M0 |
| IV    | T4     | Any N      | M0 |
|       | Any T  | N3         | M0 |
|       | Any T  | Any N      | M1 |


\*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

## Management - 1

- Multidisciplinary Team, experienced with DMM
- Rx Options include:
  - **Surgery**
  - RT
  - Chemo
  - Multimodality Rx for selected pts (stages II-III, medically operable, performance status 0)
- **Pre-Rx evaluation** includes:
  - Chest & abdo CT with IV contrast
  - PET scanning
  - VATS if suspicion of contralateral disease










## Management - 2

- Pts with stage I-III:
  - Respiratory Function Tests
  - Quantitative V/Q scan
  - Cardiac stress tests
- **Optional Preop tests:**
  - Mediastinoscopy or EBUS (endobronchial ultrasonography) for Needle-Bx of mediastinal LNs
  - Laparoscopy
  - Chest MRI





## Surgery - 1

- **P/D** Pleurectomy / Decortication
    - Complete removal of the involved pleura & all gross tumour
  - **EPP** Extrapleural Pneumonectomy (or Pleuro-pneumonectomy):
    - En-bloc resection of the involved pleura, lung, ipsilateral hemidiaphragm and pericardium
    - High mortality ( ≈ 15%) & morbidity
  - Neither Op will yield an R<sub>0</sub> resection
- 



## Surgery - 2

- Recent retrospective analysis (n=663): type of surgery did not affect survival regardless of even early stage of disease
  - Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant Pleural Mesothelioma. *J Clin Oncol* **2009**; 27: 2081-90
  - Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy vs. pleurectomy/decortication in the surgical management of MPM: results in 663 pts. *J Thorac Cardiovasc Surg* **2008**; 135: 620-6
  - Papachristos IC, Jilaihawi ANA, Prakash D. Results with radical resection in the management of malignant mesothelioma. 2<sup>nd</sup> International Congress on Lung Cancer, Crete, Greece. 9-15 Nov **1996** (n = 56 pts in 2 groups)
- P/D is more recommended than EPP in most cases



## Surgery: any **Role** for it...?!

- DIAGNOSTIC role for Surgery:
  - VATS biopsy
- Therapeutic Attempt with:
  - P/D by VATS - Impractical (?)
- Palliative Rx with:
  - VATS Pleurodesis either by:
    - Abrasion
    - Talc
    - Chemical other




VATS – Biopsy of Pleura

## ***PHOTOGRAPHS***



### **Technique**



- Double-lumen ET tube
- Lateral decubitus position
- Pleural cavity inspected







## Single port with 5 mm telescope

- Direct
- Asbes




## Adhesions being lysed

- Long scissors
- Cautery attachment





## Pleural plaques

- Along Diaphragmatic & Mediastinal pleural surfaces



## Large pleural Bx specimen


- Bleeding controllable by electrocautery
- Up to 2 x 3 cm







## Talc pleurodesis

- The talc disperses & adheres readily to all pleural surfaces, as VATS





## Flimsy, thin & membranous Adhesions

- They can be sharply divided by scissors
- Electrocautery would be needed for thick & vascular adhesions



## Endo Shears used to lyse adhesions between:

- pulmonary Parenchyma & chest wall
- the fissures



Adhesions

